erlotinib hydrochloride has been researched along with Urethral Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adkins, J; Aldrich, J; Baker, A; Barrett, MT; Borad, MJ; Bryce, AH; Carpten, JD; Cherni, I; Cheville, J; Christoforides, A; Condjella, RM; Craig, DW; Cuyugan, L; Egan, JB; Fonseca, R; Halfdanarson, TR; Ho, TH; Hunt, KS; Izatt, T; Kurdoglu, A; Liang, WS; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Nasser, S; Patel, MD; Reiman, R; Ritacca, NR; Schneider, DE; Silva, AC; Stanton, ML; Stewart, AK; Swanson, S; Von Hoff, DD; Young, SW | 1 |
1 other study(ies) available for erlotinib hydrochloride and Urethral Neoplasms
| Article | Year |
|---|---|
Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.
Topics: Adenocarcinoma, Mucinous; Aged; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Metastasis; Precision Medicine; Sequence Analysis, DNA; Up-Regulation; Urethral Neoplasms | 2017 |